CN106727971A - A kind of medicine for treating bacterial pneumonia - Google Patents
A kind of medicine for treating bacterial pneumonia Download PDFInfo
- Publication number
- CN106727971A CN106727971A CN201611252816.9A CN201611252816A CN106727971A CN 106727971 A CN106727971 A CN 106727971A CN 201611252816 A CN201611252816 A CN 201611252816A CN 106727971 A CN106727971 A CN 106727971A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- bacterial pneumonia
- tracheloside
- arecaline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 201000001178 Bacterial Pneumonia Diseases 0.000 title claims abstract description 37
- LWYAMIUSVGPFKS-CGLYQLBNSA-N Tracheloside Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)(O)C(=O)OC1 LWYAMIUSVGPFKS-CGLYQLBNSA-N 0.000 claims abstract description 38
- LKMNXYDUQXAUCZ-UHFFFAOYSA-N sinensetin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C=C2O1 LKMNXYDUQXAUCZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Natural products OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 claims abstract description 27
- LWYAMIUSVGPFKS-UHFFFAOYSA-N 2-Hydroxy-arctiin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(OC3C(C(O)C(O)C(CO)O3)O)=CC=2)(O)C(=O)OC1 LWYAMIUSVGPFKS-UHFFFAOYSA-N 0.000 claims abstract description 19
- QEWSAPKRFOFQIU-UHFFFAOYSA-N 5-Hydroxy-6,7,3',4'-tetramethoxyflavone Natural products C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C=C2O1 QEWSAPKRFOFQIU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241000931705 Cicada Species 0.000 claims abstract description 19
- JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 claims abstract description 19
- 229920000061 Geraniin Polymers 0.000 claims abstract description 19
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 19
- 240000000249 Morus alba Species 0.000 claims abstract description 19
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims abstract description 19
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 19
- DRLZZQRQMWQRLZ-UHFFFAOYSA-N 6-C-Arabinosyl-8-C-glucosyl apigenin Natural products OCC1OC(C(O)C1O)c2c(O)c(C3OC(CO)C(O)C(O)C3O)c4OC(=CC(=O)c4c2O)c5ccc(O)cc5 DRLZZQRQMWQRLZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- OVMFOVNOXASTPA-UHFFFAOYSA-N Neoisoschaftoside Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C(C(O)C(O)CO2)O)=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O OVMFOVNOXASTPA-UHFFFAOYSA-N 0.000 claims abstract description 18
- RBVAFYCFAFADAG-UHFFFAOYSA-N Orientin Natural products OCC1OC(C(O)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4)C(O)C1O RBVAFYCFAFADAG-UHFFFAOYSA-N 0.000 claims abstract description 18
- LKYNAQSYQLFTCM-GYXNDICUSA-N [(6r)-6-hydroxy-2-methyl-5-oxo-6-[(2s,3s,8s,9r,10r,13r,14s,16r,17r)-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-11-oxo-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptan-2-yl] acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)[C@@H](O)C2(C)C LKYNAQSYQLFTCM-GYXNDICUSA-N 0.000 claims abstract description 18
- AQEGCOVXDRJSKR-UHFFFAOYSA-N cucurbitacin IIa Natural products CC(=O)OC(C)(C)CCC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(CC(O)C(O)C4(C)C)C3(C)CCC12C AQEGCOVXDRJSKR-UHFFFAOYSA-N 0.000 claims abstract description 18
- OVMFOVNOXASTPA-ZUGZFPASSA-N iso-schaftoside Natural products O=C1c2c(O)c([C@H]3[C@@H](O)[C@@H](O)[C@@H](O)CO3)c(O)c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c2OC(c2ccc(O)cc2)=C1 OVMFOVNOXASTPA-ZUGZFPASSA-N 0.000 claims abstract description 18
- OVMFOVNOXASTPA-VYUBKLCTSA-N isoschaftoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C([C@H]2[C@@H]([C@@H](O)[C@@H](O)CO2)O)=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O OVMFOVNOXASTPA-VYUBKLCTSA-N 0.000 claims abstract description 18
- MMDUKUSNQNWVET-UHFFFAOYSA-N schaftozide Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C(C(O)C(O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MMDUKUSNQNWVET-UHFFFAOYSA-N 0.000 claims abstract description 18
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 claims abstract description 17
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 claims abstract description 17
- -1 hydroxyl morindone Chemical compound 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 125000002252 acyl group Chemical group 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- VGGSULWDCMWZPO-ODEMIOGVSA-N Spinosin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=2C(=O)C=C(OC=2C=C1OC)C=1C=CC(O)=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VGGSULWDCMWZPO-ODEMIOGVSA-N 0.000 claims description 25
- VGGSULWDCMWZPO-UHFFFAOYSA-N flavoayamenin Natural products COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1C1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O VGGSULWDCMWZPO-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000012467 final product Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 5
- 229930182470 glycoside Natural products 0.000 claims 3
- 150000002338 glycosides Chemical class 0.000 claims 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- 241000675108 Citrus tangerina Species 0.000 claims 1
- 241001522083 Citrus trifoliata Species 0.000 claims 1
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 206010035664 Pneumonia Diseases 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010071699 Infectious pleural effusion Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002829 antibacterial sensitivity test Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of medicine for treating bacterial pneumonia, the medicine of the treatment bacterial pneumonia is according to the primary raw material of weight portion：26 parts of cicada slough, 36 40 parts of the root bark of white mulberry, 26 parts of different sinensetin, 6 10 parts of geraniin, 25 30 parts of poncirin, 7 14 parts of arecaline, 23 parts of cucurbitacin IIA, 6 29 31 parts of asafoetide acyl spinosins, 24 parts of Isoschaftoside, 24 parts of 3 hydroxyl morindone, 0.1 0.6 parts of tracheloside.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of bacterial pneumonia, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of medicine for treating bacterial pneumonia.
Background technology
Bacterial pneumonia is most common pneumonia, is also one of most common infectious diseases.It mainly includes pneumonia chain
Coccus, staphylococcus aureus, α-hemolytic streptococcus, klebsiella pneumoniae, haemophilus influenzae, pseudomonas aeruginosa
Pneumonia etc..Health threat to children and the elderly is very big.By anatomical classification, pneumonia can be divided into great Ye, it is lobular and
Matter.It is now to press etiological classification, main infectious and physics and chemistry such as radioactive ray, poison gas, medicine and metamorphosis for ease for the treatment of more
Reactivity such as hylactic pneumonia, it is bacterium, virus, Chlamydia, mycoplasma, Richettsia, fungi that clinical findings is most
The infectious pneumonia caused with parasite etc., wherein most commonly seen with bacterium.The pathogen of pneumonia is because of age, with disease
With immune functional state, acquisition pattern and have larger difference.The common causative of community acquired pneumonia is streptococcus pneumonia, stream
Haemophilus influenza, staphylococcus aureus, micrococcus scarlatinae, Legionella, anaerobic bacteria and virus, mycoplasma and Chlamydia
Deng, and then with Pseudomonas aeruginosa and other pseudomonads, pneumobacillus, Escherichia coli, cloaca and generation intestines bar in nosocomial pneumonia in patients
Bacterium, proteus, Methicillin-resistant Staphylococcus aureus (MRSA) and fungi etc. are common.Most of aspiration pneumonia is anaerobic infection.
Lack effective medicine at present.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating bacterial pneumonia, to solve to be proposed in above-mentioned background technology
Problem.
To achieve the above object, the present invention provides following technical scheme：
A kind of medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：Cicada slough 2-6 parts, root bark of white mulberry 36-40
Part, different sinensetin 2-6 parts, geraniin 6-10 parts, poncirin 25-30 parts, arecaline 7-14 parts, cucurbitacin IIA2-3 parts, 6-
29-31 parts of asafoetide acyl spinosin, Isoschaftoside 2-4 parts, 2-4 parts, tracheloside 0.1-0.6 parts of 3- hydroxyl morindones.
As further scheme of the invention：The medicine of the treatment bacterial pneumonia, according to the primary raw material of weight portion
For：Cicada slough 3-5 parts, root bark of white mulberry 38-39 parts, different sinensetin 3-5 parts, geraniin 7-9 parts, poncirin 26-28 parts, arecaline 9-
12 parts, 2-3 parts of cucurbitacin IIA, 29-31 parts of 6- asafoetides acyl spinosin, Isoschaftoside 2-4 parts, 3- hydroxyl morindones 2-4
Part, tracheloside 0.2-0.5 parts.
As further scheme of the invention：The medicine of the treatment bacterial pneumonia, according to the primary raw material of weight portion
For：4 parts of cicada slough, 39 parts of the root bark of white mulberry, 4 parts of different sinensetin, 8 parts of geraniin, 27 parts of poncirin, 11 parts of arecaline, cucurbitacin IIA
3 parts, 30 parts of 6- asafoetide acyls spinosin, 3 parts of Isoschaftoside, 3 parts of 3- hydroxyls morindone, 0.4 part of tracheloside.
A kind of preparation method of the medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh cicada slough, the root bark of white mulberry, different sinensetin, geraniin,
Poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving,
Machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low after mixing
Temperature is dried, and at 4-8 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of bacterial pneumonia, so as to reach comprehensively
The purpose of rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：It is 2 parts of cicada slough, 36 parts of the root bark of white mulberry, different
2 parts of sinensetin, 6 parts of geraniin, 25 parts of poncirin, 7 parts of arecaline, 2 parts of cucurbitacin IIA, 6- asafoetide acyls spinosin 29
Part, 2 parts of Isoschaftoside, 2 parts of 3- hydroxyls morindone, 0.1 part of tracheloside.
A kind of preparation method of the medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh cicada slough, the root bark of white mulberry, different sinensetin, geraniin,
Poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving,
Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature after mixing
Dry, at 4 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 2
A kind of medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：It is 3 parts of cicada slough, 38 parts of the root bark of white mulberry, different
3 parts of sinensetin, 7 parts of geraniin, 26 parts of poncirin, 9 parts of arecaline, 2 parts of cucurbitacin IIA, 6- asafoetide acyls spinosin 29
Part, 2 parts of Isoschaftoside, 2 parts of 3- hydroxyls morindone, 0.2 part of tracheloside.
A kind of preparation method of the medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh cicada slough, the root bark of white mulberry, different sinensetin, geraniin,
Poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving,
Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature after mixing
Dry, at 4 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 3
A kind of medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：It is 4 parts of cicada slough, 39 parts of the root bark of white mulberry, different
4 parts of sinensetin, 8 parts of geraniin, 27 parts of poncirin, 11 parts of arecaline, 3 parts of cucurbitacin IIA, 6- asafoetide acyls spinosin 30
Part, 3 parts of Isoschaftoside, 3 parts of 3- hydroxyls morindone, 0.4 part of tracheloside.
A kind of preparation method of the medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh cicada slough, the root bark of white mulberry, different sinensetin, geraniin,
Poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving,
Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 6min, controls RSD≤5%, compressing tablet and low temperature after mixing
Dry, at 6 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 4
A kind of medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：It is 5 parts of cicada slough, 39 parts of the root bark of white mulberry, different
5 parts of sinensetin, 9 parts of geraniin, 28 parts of poncirin, 12 parts of arecaline, 3 parts of cucurbitacin IIA, 6- asafoetide acyls spinosin 31
Part, 4 parts of Isoschaftoside, 4 parts of 3- hydroxyls morindone, 0.5 part of tracheloside.
A kind of preparation method of the medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh cicada slough, the root bark of white mulberry, different sinensetin, geraniin,
Poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving,
Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature after mixing
Dry, at 8 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 5
A kind of medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：It is 6 parts of cicada slough, 40 parts of the root bark of white mulberry, different
6 parts of sinensetin, 10 parts of geraniin, 30 parts of poncirin, 14 parts of arecaline, 3 parts of cucurbitacin IIA, 6- asafoetide acyls spinosin 31
Part, 4 parts of Isoschaftoside, 4 parts of 3- hydroxyls morindone, 0.6 part of tracheloside.
A kind of preparation method of the medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh cicada slough, the root bark of white mulberry, different sinensetin, geraniin,
Poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving,
Machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature after mixing
Dry, at 8 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
Pharmacology test
1st, chronic toxicity test
It is experiment with medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, successive administration 2 times in 24h,
Per minor tick 8h, 400mg/kg doses are administered every time, daily accumulation medicine total amount reaches 800mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland,
Stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：Medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
It is experiment with medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, medicine of the present invention is divided into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 80,160,240mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.Result shows：Medicine of the present invention does not find overt toxicity reaction and postpones in long term toxicity test
Toxic reaction.It can be seen that, medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical test
In April, 2015, in Nanjing, 200 patients screened in hospital in May, 2015, and all patients meet bacillary lung
Scorching illness.Wherein male 105, women 95, minimal ages 8 years old, max age 75 years old, average age 41.7 years old.All trouble
Person takes the medicine of the preparation of the embodiment of the present invention 3, and instructions of taking is：Daily 8mg/kg, 3 days courses for the treatment of treat two treatments altogether
Journey.
Diagnostic criteria：(1) chest X-ray：It is most common to show as the change of Bronchopneumonia type, generally it is helpless to pneumonia disease
The determination of original, but some features can have suggested to diagnosis, and such as lobe of the lung consolidation, cavity formation or relatively large pleural effusion are more common in
Bacterial pneumonia.Staphylococcal pneumonia can cause obvious lung tissue necrosis, lung qi capsule, pulmonary abscess and pyothorax.Grain-negative bar
Bacterium pneumonia is often in LLB pneumonia type, easily forms multiple small vomica.(2) bacteriology checking：Phlegm or hydrothorax plate coating checking,
Culture pathogenic bacteria and antibiotic sensitivity test are for continuous 2,3 times same bacterial growth, and the possibility of pathogenic bacteria is big, only once sun
Property or be repeatedly different bacterium growth, then poor reliability.Bacterial concentration >=107Cfa/ml is pathogenic bacteria, 105~107Cfa/ml is
It is suspicious,<105Cfa/ml is generally contaminated bacteria.(3) blood test：White blood cell count(WBC) and neutrophil leucocyte generally increase, and can have core
Move to left, old or several cases white blood cell count(WBC) can not increase.(4) immunologic test：With immunofluorescence, enzyme linked immunological suction
The methods such as adhesion test, counter immunoelectrophoresis detect the antigen or antibody of serum pathogen, help diagnosis.Polymerase chain reaction is to disease
The detection of substance has certain meaning.(5) other check the correlations such as row blood gas analysis if necessary, Liver and kidney function, serum electrolyte
Check.
Curative effect determinate standard：Clinical symptoms all disappear, and laboratory checks normal.Take a turn for the better：Clinical symptom relief, the state of an illness is obtained
To control, laboratory examination improvement or normal.It is invalid：No significant improvement or aggravated in clinical symptoms.
Therapeutic effect：200 patients, cure 168, take a turn for the better 20, invalid 12, total effective rate 94.0%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of medicine for treating bacterial pneumonia, it is characterised in that the primary raw material according to weight portion is：Cicada slough 2-6 parts, mulberry
White 36-40 parts of skin, different sinensetin 2-6 parts, geraniin 6-10 parts, poncirin 25-30 parts, arecaline 7-14 parts, cucurbitacin IIA
2-3 parts, 29-31 parts of 6- asafoetides acyl spinosin, Isoschaftoside 2-4 parts, 2-4 parts of 3- hydroxyl morindones, tracheloside 0.1-0.6
Part.
2. it is according to claim 1 treatment bacterial pneumonia medicine, it is characterised in that the treatment bacterial pneumonia
Medicine, be according to the primary raw material of weight portion：Cicada slough 3-5 parts, root bark of white mulberry 38-39 parts, different sinensetin 3-5 parts, geraniin 7-9
Part, poncirin 26-28 parts, arecaline 9-12 parts, 2-3 parts of cucurbitacin IIA, 29-31 parts of 6- asafoetides acyl spinosin, different summer Buddhist
2-4 parts of tower glycosides, 2-4 parts, tracheloside 0.2-0.5 parts of 3- hydroxyl morindones.
3. it is according to claim 1 and 2 treatment bacterial pneumonia medicine, it is characterised in that the bacillary lung for the treatment of
Scorching medicine, be according to the primary raw material of weight portion：4 parts of cicada slough, 39 parts of the root bark of white mulberry, 4 parts of different sinensetin, 8 parts of geraniin, Chinese holly
27 parts of tangerine glycosides, 11 parts of arecaline, 3 parts of cucurbitacin IIA, 30 parts of 6- asafoetide acyls spinosin, 3 parts of Isoschaftoside, 3- hydroxyl bars
3 parts of halberd quinone, 0.4 part of tracheloside.
4. it is a kind of as described in claim 1-3 is any treatment bacterial pneumonia medicine preparation method, it is characterised in that tool
Body step is：
First, in pharmaceutical grade clean area, cicada slough, the root bark of white mulberry, different sinensetin, geraniin, trifoliate orange are weighed by above-mentioned metering ratio
Glycosides, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, sieving, machinery
Ultra-pure water is added after mixing, is placed in pharmacy mixer, mix 4-8min, control RSD≤5%, compressing tablet simultaneously do by low temperature after mixing
Dry, at 4-8 DEG C, packaging obtains final product the medicine for the treatment of bacterial pneumonia to temperature control.
5. it is according to claim 4 treatment bacterial pneumonia medicine preparation method, it is characterised in that in specific steps
Mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611252816.9A CN106727971A (en) | 2016-12-30 | 2016-12-30 | A kind of medicine for treating bacterial pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611252816.9A CN106727971A (en) | 2016-12-30 | 2016-12-30 | A kind of medicine for treating bacterial pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727971A true CN106727971A (en) | 2017-05-31 |
Family
ID=58928541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611252816.9A Pending CN106727971A (en) | 2016-12-30 | 2016-12-30 | A kind of medicine for treating bacterial pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727971A (en) |
-
2016
- 2016-12-30 CN CN201611252816.9A patent/CN106727971A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103156826B (en) | The purposes of patchouli alcohol | |
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN101053600B (en) | Medicinal composition for treating cough and preparation method and application thereof | |
| CN102058660B (en) | Application of patchouli oil in preparing drugs for treating bacterial infectious diseases | |
| CN1686185A (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
| CN103933350B (en) | Use of rhizoma bletillae ethyl acetate extract | |
| CN106727643A (en) | A kind of Western medicine for treating bacterial pneumonia | |
| CN101972391A (en) | Medicinal composition used for treating swine mastitis and preparation method thereof | |
| CN101537011B (en) | Pharmaceutical composition for preventing or treating parkinsonism and preparation method thereof | |
| CN106727971A (en) | A kind of medicine for treating bacterial pneumonia | |
| CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
| CN106728302A (en) | A kind of Chinese and Western medicine combination for treating bacterial pneumonia and preparation method thereof | |
| CN104337847A (en) | Compound medicine containing bracken and fosfomycin for livestock | |
| CN101085048B (en) | Traditional Chinese medicine for detoxicating for animals and preparation method thereof | |
| CN113116938A (en) | Quadruple viable bacteria preparation and application thereof | |
| CN101810675A (en) | Medicament for treating pharyngitis | |
| CN103263523B (en) | A kind of for breast perfusion preparation preventing and treating mastitis and preparation method thereof | |
| CN113662950B (en) | Application of saponin in preparation of anti-mycoplasma bovis product | |
| CN102772542B (en) | Compound buccal tablet used for preventing oral diseases | |
| CN101361846A (en) | Detoxification fever-reduction traditional Chinese medicine for treating internal medical excess fire disease and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |
|
| WD01 | Invention patent application deemed withdrawn after publication |